{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-007711","form_type":"8-K","ticker":"GOVX","cik":"0000832489","company_name":"GeoVax Labs, Inc.","filed_at":"2023-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.218427+00:00","generated_at":"2026-06-17T17:22:22.137586+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"GeoVax 2022 net loss $14.0M, cash $27.6M; clinical trials expand","bullets":["Net loss for 2022 was $14.0M, versus $18.6M in 2021; R&D expenses fell to $9.1M from $15.6M.","Cash balance at Dec 31, 2022: $27.6M, up from $11.4M in 2021; raised $35.4M from equity and warrant exercises.","Phase 1/2 trial of Gedeptin® for advanced head & neck cancer expanded to three NCI Cancer Centers.","GEO-CM04S1 COVID-19 vaccine advancing in two Phase 2 trials; data show robust T cell and antibody responses."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-007711","json":"https://secwatch.observer/filing/0001437749-23-007711.json","markdown":"https://secwatch.observer/filing/0001437749-23-007711.md","text":"https://secwatch.observer/filing/0001437749-23-007711.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/832489/000143774923007711/0001437749-23-007711-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/832489/000143774923007711/govx20230323_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T17:22:22.137586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8b78bc0120b52cd588928b73c744a614d1234c18","claim":"GeoVax Labs, Inc. reported financial results for the year ended December 31, 2022.","evidence_excerpt":"On March 23, 2023, GeoVax Labs, Inc. (the “Company”) issued a press release reporting its results of operations for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/832489/000143774923007711/0001437749-23-007711-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}